Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care Conference
02. März 2018 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., March 02, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage pharmaceutical company developing and commercializing novel antibiotics to treat...
Melinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018
28. Februar 2018 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ (meropenem and vaborbactam) in Patients with cUTI
27. Februar 2018 16:05 ET
|
Melinta Therapeutics
- VABOMERE demonstrated a greater numerical overall success rate vs piperacillin-tazobactam - VABOMERE safety profile comparable to piperacillin-tazobactam NEW HAVEN, Conn., Feb. 27, 2018 (GLOBE...
Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina
20. Februar 2018 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States
29. Januar 2018 07:00 ET
|
Melinta Therapeutics
– Approved for adult patients with acute bacterial skin and skin structure infections (ABSSSI) – – Provides coverage of gram-positive and gram-negative pathogens; only FDA-approved fluoroquinolone...
Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis
18. Januar 2018 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Completes Acquisition of The Medicines Company’s Infectious Disease Portfolio
08. Januar 2018 07:00 ET
|
Melinta Therapeutics
— Expands portfolio to four marketed antibiotics, with peak sales potential over $1 billion —— Creates premier commercial stage global antibiotic franchise with the addition of Vabomere™(meropenem and...
Melinta Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
03. Januar 2018 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Appoints Lisa DeFrancesco as Senior Vice President of Investor Relations
02. Januar 2018 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing, and commercializing novel antibiotics to treat...
Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company
29. November 2017 07:00 ET
|
Melinta Therapeutics
- Acquisition positions Melinta as durable and focused pure-play antibiotics company with four marketed products: Baxdela®, Vabomere®, Orbactiv®, and Minocin IV® - - Peak sales potential of the...